HeartFlow raises $215M to keep up with growing demand

Michael Walter | April 07, 2023 | Cardiovascular Business | Artificial Intelligence

An example of the FFR-CT technology from Heartflow. The vendor's AI can take a patient's cardiac CT scan and non-invasively assess FFR hemodynamic flow for all the coronary arteries to determine if blockages are significant enough to require revascularization.

HeartFlow, the California-based healthcare technology company known for its FFR-CT technology, has announced the completion of a Series F funding round worth $215 million by its parent company, HeartFlow Holding.

The funding round was led by Bain Capital Life Sciences. A new investor, Janus Henderson Investors, also participated, as did Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management.

HeartFlow plans to use the new financing to help keep up with its rapid growth and expand sales of its artificial intelligence-powered solutions, including RoadMap Analysis and Plaque Analysis, which were both cleared by the U.S. Food and Drug Administration in October 2022.

“The oversubscription of our Series F funding round, particularly in the current market backdrop, is a strong validation of our technology, our team and the opportunity in front of us,” HeartFlow CEO John Farquhar said in a prepared statement. “We appreciate the support of our investors, both existing and new, who share HeartFlow's vision to build a new standard of care for people at risk of heart disease.”

“HeartFlow is a leader in precision heart care and its AI-enabled products promise to help physicians more effectively diagnose and treat heart disease, which continues to be the leading cause of death in the U.S.,” added Nicholas Downing, MD, a managing director at Bain Capital Life Sciences, in the same statement. “We look forward to supporting the company’s commitment to improving cardiovascular care for patients as it heads into this exciting next chapter of growth.”

HeartFlow’s growth reached new heights after its FFR-CT technology was included in the 2021 American College of Cardiology/American Heart Association chest pain guidelines. Watch this video from ACC.22 for additional context.

AI-powered CCTA outperforms usual care when evaluating stable chest pain

HeartFlow gains FDA clearance for 2 new AI-powered imaging assessments

VIDEO: HeartFlow FFR-CT sees increased interest after inclusion in the 2021 Chest Pain Guidelines

‘A watershed moment’: HeartFlow praises new chest pain guidelines

ACC, AHA release long-awaited chest pain guidelines

New clinical trial focused on AI-powered CAD evaluations opens enrollment

Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Exec

Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business

U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.